NHS patients with type 2 diabetes in England and Wales are set to have access to a new treatment option after Johnson & Johnson's Invokana passed one of its final access hurdles.

NICE has issued a final appraisal determination recommending the drug to reduce blood sugar levels in people unable to achieve adequate control via diet and lifestyle changes or treatment with other products.

Invokana (canagliflozin) is already available in the UK in a limited capacity after Janssen – J&J's pharma division – launched the drug in February when it had only received positive draft guidance from NICE.

For more details, go to:http://www.pmlive.com/pharma_news/invokana_set_for_nice_recommendation_569568